3.48MMarket Cap-1.89P/E (TTM)
2.0000High1.7600Low163.87KVolume2.0000Open1.7700Pre Close299.70KTurnover8.73%Turnover RatioLossP/E (Static)1.92MShares18.719252wk High1.33P/B3.40MFloat Cap1.660052wk Low--Dividend TTM1.88MShs Float329609.2800Historical High--Div YieldTTM13.56%Amplitude1.6600Historical Low1.8280Avg Price1Lot Size
Sonnet BioTherapeutic Stock Forum
any chance of rise short term?
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sal...
📊⚡️📊
📊⚡️📊
hault up ❤️🌹🌹🌹🌹
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
Monday, 9th December at 8:45 am
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and i...
No comment yet